The specific aims of the Heartland Cancer Research NCORP are to: (1)To be the primary vector for delivering;implementing, and executing NCI approved cancer treatment clinical trials to a large Midwestern rural and urban population; (2) To be the primary vector for delivering, implementing, and executing NCI approved cancer prevention, screening and control clinical trials to a large Midwestern rural and urban population; (3) To be the primary vector for delivering, implementing, and executing NCI approved Cancer Care Delivery Research clinical trials to a large Midwestern rural and urban population; (4) Enhance Midwestern cancer care by implementing a region-wide high standard of multidisciplinary integrated cancer care delivery; (5) Improve the education and outreach to all healthcare providers across rural and urban Illinois and Missouri regarding cancer clinical trials and incorporation of new research findings into daily patient care; (6) Improve cancer prevention, treatment, and survivorship education for healthcare professionals throughout Illinois and Missouri; (7) Perform breakthrough research in methods to improve the efficacy, efficiency, and cost effectiveness of cancer care delivery for a large region across Illinois and Missouri; (8) Reach out to underserved and vulnerable populations across Illinois and Missouri to improve access to cancer clinical trials, state of the art care, and cancer prevention and earl detection strategies; (9) Coordinate with local and state agencies to leverage resources to improve state wide cancer education regarding cancer prevention, early detection, treatment and clinical trials; (10) Continue to explore best practices for improving the productivity of Heartland NCORP within an environment of limited resources; (11) Continue to recruit, train, and support new investigators who share the vision and embrace the objectives of the Heartland NCORP

Public Health Relevance

The Heartland Cancer Research NCORP (Heartland NCORP) will be the premier community cancer research organization of the states of Illinois and Missouri by providing state of the art cancer clinical trials, cancer care delivery research, interdisciplinary cancer treatment planning, and coordinated biomarker driven research throughout our service region.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
1UG1CA189830-01
Application #
8790489
Study Section
Special Emphasis Panel (ZCA1-RTRB-E (M1))
Program Officer
Xie, Heng
Project Start
2014-08-01
Project End
2019-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
1
Fiscal Year
2014
Total Cost
$2,520,862
Indirect Cost
$226,227
Name
Decatur Memorial Hospital
Department
Type
DUNS #
046584991
City
Decatur
State
IL
Country
United States
Zip Code
62526
Schott, Anne F; Barlow, William E; Van Poznak, Catherine H et al. (2016) Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Res Treat 159:87-95
Press, Oliver W; Li, Hongli; Schöder, Heiko et al. (2016) US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol 34:2020-7
Lara Jr, Primo N; Moon, James; Hesketh, Paul J et al. (2016) SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. J Thorac Oncol 11:420-5
Belani, Chandra P; Dahlberg, Suzanne E; Rudin, Charles M et al. (2016) Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer 122:2371-8
Stephens, Deborah M; Li, Hongli; LeBlanc, Michael L et al. (2016) Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. J Clin Oncol 34:2997-3004
Puvvada, Soham D; Li, Hongli; Rimsza, Lisa M et al. (2016) A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leuk Lymphoma 57:2359-69
Till, Brian G; Li, Hongli; Bernstein, Steven H et al. (2016) Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol 172:208-18
Zent, Clive S; Victoria Wang, Xin; Ketterling, Rhett P et al. (2016) A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908). Am J Hematol 91:308-12
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42

Showing the most recent 10 out of 12 publications